Clinical Takeaway
Cannabinoid-based treatments, including CBD-rich preparations, have shown promising early results for reducing certain behavioral symptoms in autism spectrum disorder, such as irritability, hyperactivity, and self-injurious behaviors. However, the current body of randomized controlled trial evidence remains limited in scale and methodological consistency, making definitive clinical recommendations premature. Clinicians should approach cannabinoid therapy for ASD as an emerging option that warrants careful, individualized consideration alongside ongoing monitoring.
#16 Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.
Citation: Riera Rachel et al.. Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.. Journal of clinical pharmacology. 2025. PMID: 40605143.
Design: 5 Journal: 0 N: 0 Recency: 2 Pop: 3 Human: 1 Risk: 0
Abstract: Autism spectrum disorders are characterized by some difficulties with social interactions and communication, atypical patterns of behavior, and unusual reactions to emotions. Studies have found promising results regarding the effects of cannabis on autism. We conducted a systematic review of randomized clinical trials on the effects of cannabis derivatives and their analogs for autism. This review was developed according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to PRISMA 2020. The protocol was prospectively published in the PROSPERO database (CRD42023468300). We included randomized controlled trials with autism-diagnosed participants treated with any cannabis derivate or its analogs for therapeutic purposes. Two reviewers assessed titles and abstracts independently and potentially eligible full texts were assessed to confirm eligibility. After that, they extracted data using a standardized worksheet. Searches retrieved 1264 references, only 11 RCTs were included, four with available results for children/adolescents with autism. Five different cannabis presentations were tested. One trial pointed that cannabis may improve global assessment symptoms, but for other outcomes results were uncertain. No included study assessed quality of life. The certainty of evidence ranged from very low to low certainty for the assessed outcomes. Cannabis whole plant extract may improve global assessment symptoms, but the different cannabis presentations, outcome assessments and very low certainty of evidence from the included studies make it difficult to draw conclusions about cannabis for people with autism. This scenario of uncertainties impacts directly clinical practice and decision making.
What This Study Teaches Us
A systematic review of 11 randomized trials found only weak evidence that cannabis whole plant extract may improve global autism symptoms, but the evidence quality is very low and results for other outcomes remain uncertain. No study measured quality of life, and five different cannabis formulations were tested, making it impossible to recommend a standard approach.
Why This Matters Clinically
Clinicians are increasingly asked by families about cannabis for autism, but this review shows we lack the rigorous data needed to answer confidently. The very low certainty of evidence should anchor honest conversations with patients about what we actually know versus what we hope might work.
Study Snapshot
| Study Design | Systematic review of randomized controlled trials following Cochrane methodology and PRISMA 2020 reporting standards |
| Population | People diagnosed with autism spectrum disorder (4 trials included children/adolescents; total N and full demographic breakdown not specified in abstract) |
| Intervention | Five different cannabis presentations tested (specific formulations, doses, and durations not detailed in abstract) |
| Primary Outcome | Global assessment of autism symptoms and other symptom-specific outcomes |
| Key Result | Only one trial showed cannabis whole plant extract may improve global assessment symptoms; other outcomes uncertain; certainty of evidence ranged from very low to low |
Where This Paper Deserves Skepticism
The abstract is thin on critical details, but even so, red flags are clear: only 4 of 11 RCTs had usable data on children with autism; five different cannabis presentations make comparing apples to apples impossible; the authors explicitly state the certainty of evidence is very low to low. The fact that no included trial measured quality of life (arguably the most patient-relevant outcome) suggests the evidence base was either very new or poorly designed. With only 1264 references screened to yield 11 RCTs, the field appears sparse and methodologically uneven.
Dr. Caplan’s Take
I read this as a cautionary tale, not a green light. Yes, there’s a whiff of signal from one trial on global symptoms, but the heterogeneity in cannabis products, the very low certainty ratings, and the small number of usable trials tell me we’re still in hypothesis-generating territory. Cannabis may help some children with autism, but I cannot yet tell a family which product, at what dose, for which symptoms, or with what confidence. Until we have larger, well-designed, placebo-controlled trials using standardized products and validated outcome measures, cannabis for autism remains experimental and should be framed that way in clinical conversations.
Clinical Bottom Line
Current evidence does not support recommending cannabis as a standard treatment for autism spectrum disorder. Families interested in this option deserve transparency about the very low quality and inconsistency of existing data, and any trial should be undertaken with realistic expectations and close monitoring.
| |
Have thoughts on this? Share it:
